CoChat

Metformin suppresses adipogenesis through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms

Open access
Chen, Suet Ching, Brooks, Rebecca, Houskeeper, Jessica, Bremner, Shaun K., Dunlop, Julia, Viollet, Benoit, Logan, Pamela J., Salt, Ian P., Ahmed, S. Faisal, Yarwood, Stephen J. · 2017 · Molecular and Cellular Endocrinology
Cited by 127

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

People with Type 2 diabetes mellitus (T2DM) have reduced bone mineral density and an increased risk of fractures due to altered mesenchymal stem cell (MSC) differentiation in the bone marrow. This leads to a shift in the balance of differentiation away from bone formation (osteogenesis) in favour of fat cell development (adipogenesis). The commonly used anti-diabetic drug, metformin, activates the osteogenic transcription factor Runt-related transcription factor 2 (Runx2), which may suppress adipogenesis, leading to improved bone health. Here we investigate the involvement of the metabolic enzyme, AMP-activated protein kinase (AMPK), in these protective actions of metformin. The anti-adipogenic actions of metformin were observed in multipotent C3H10T1/2 MSCs, in which metformin exerted reciprocal control over the activities of Runx2 and the adipogenic transcription factor, PPARγ, leading to suppression of adipogenesis. These effects appeared to be independent of AMPK activation but rather through the suppression of the mTOR/p70S6K signalling pathway. Basal AMPK and mTOR/p70S6K activity did appear to be required for adipogenesis, as demonstrated by the use of the AMPK inhibitor, compound C. This observation was further supported by using AMPK knockout mouse embryo fibroblasts (MEFs) where adipogenesis, as assessed by reduced lipid accumulation and expression of the adipogeneic transcription factor, C/EBPβ, was found to display an absolute requirement for AMPK. Further activation of AMPK in wild type MEFS, with either metformin or the AMPK-specific activator, A769662, was also associated with suppression of adipogenesis. It appears, therefore, that basal AMPK activity is required for adipogenesis and that metformin can inhibit adipogenesis through AMPK-dependent or -independent mechanisms, depending on the cellular context.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mce.2016.11.011

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 41

  1. Banerjee, 1997, Runt homology domain proteins in osteoblast differentiation: AML3/CBFA1 is a major component of a bone-specific complex, J. Cell Biochem., 66, 1, 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V · DOI · Paper page
  2. Bang, 2014, Convergence of IPMK and LKB1-AMPK signaling pathways on metformin action, Mol. Endocrinol., 28, 1186, 10.1210/me.2014-1134 · DOI · Paper page
  3. Chen, 2016, Fate decision of mesenchymal stem cells: adipocytes or osteoblasts?, Cell Death Differ., 0000023, 1128, 10.1038/cdd.2015.168 · DOI · Paper page
  4. Cool, 2006, Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome, Cell Metab., 3, 403, 10.1016/j.cmet.2006.05.005 · DOI · Paper page
  5. Cortizo, 2006, Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture, Eur. J. Pharmacol., 536, 38, 10.1016/j.ejphar.2006.02.030 · DOI · Paper page
  6. Cusi, 1996, Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus, J. Clin. Endocrinol. Metab., 81, 4059
  7. Dowling, 2011, Understanding the benefit of metformin use in cancer treatment, BMC Med., 9, 33, 10.1186/1741-7015-9-33 · DOI · Paper page
  8. Fulco, 2008, Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt, Dev. Cell., 14, 661, 10.1016/j.devcel.2008.02.004 · DOI · Paper page
  9. Grey, 2007, The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial, J. Clin. Endocrinol. Metab., 92, 1305, 10.1210/jc.2006-2646 · DOI · Paper page
  10. Habinowski, 2001, The effects of AICAR on adipocyte differentiation of 3T3-L1 cells, Biochem. Biophys. Res. Commun., 286, 852, 10.1006/bbrc.2001.5484 · DOI · Paper page
  11. Hothersall, 2013, Contemporary risk of hip fracture in type 1 and type 2 diabetes: a national registry study from Scotland, J. Bone Min. Res.
  12. Jang, 2011, Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2, Bone, 48, 885, 10.1016/j.bone.2010.12.003 · DOI · Paper page
  13. Janghorbani, 2007, Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture, Am. J. Epidemiol., 166, 495, 10.1093/aje/kwm106 · DOI · Paper page
  14. Jeon, 2003, Activation of peroxisome proliferator-activated receptor-gamma inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts, J. Biol. Chem., 278, 23270, 10.1074/jbc.M211610200 · DOI · Paper page
  15. Kanazawa, 2008, Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression, Biochem. Biophys. Res. Commun., 375, 414, 10.1016/j.bbrc.2008.08.034 · DOI · Paper page
  16. Kilpadi, 2014, Type 2 diabetes is associated with vertebral fractures in a sample of clinic- and hospital-based Latinos, J. Immigr. Minor Health, 16, 440, 10.1007/s10903-013-9833-5 · DOI
  17. Kim, 2012, Human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by AMP-activated protein kinase, J. Cell Physiol., 227, 1680, 10.1002/jcp.22892 · DOI
  18. Kobashigawa, 2014, Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: an in vitro study, PLoS One, 9, e104888, 10.1371/journal.pone.0104888 · DOI · Paper page
  19. Lecka-Czernik, 2009, Bone as a target of type 2 diabetes treatment, Curr. Opin. Investig. Drugs, 10, 1085
  20. Lecka-Czernik, 2007, Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo, Endocrinology, 148, 903, 10.1210/en.2006-1121 · DOI · Paper page
  21. Lee, 2011, AICAR, an activator of AMPK, inhibits adipogenesis via the WNT/beta-catenin pathway in 3T3-L1 adipocytes, Int. J. Mol. Med., 28, 65
  22. Lee, 2012, Metformin regulates glucose transporter 4 (GLUT4) translocation through AMP-activated protein kinase (AMPK)-mediated Cbl/CAP signaling in 3T3-L1 preadipocyte cells, J. Biol. Chem., 287, 44121, 10.1074/jbc.M112.361386 · DOI · Paper page
  23. Lee, 2014, The osteogenic or adipogenic lineage commitment of human mesenchymal stem cells is determined by protein kinase C delta, BMC Cell Biol., 15, 42, 10.1186/s12860-014-0042-4 · DOI
  24. Morrow, 2003, Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells, J. Biol. Chem., 278, 31629, 10.1074/jbc.M212831200 · DOI · Paper page
  25. Muruganandan, 2009, Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program, Cell Mol. Life Sci., 66, 236, 10.1007/s00018-008-8429-z · DOI · Paper page
  26. Nam, 2008, Compound C inhibits clonal expansion of preadipocytes by increasing p21 level irrespectively of AMPK inhibition, Arch. Biochem. Biophys., 479, 74, 10.1016/j.abb.2008.07.029 · DOI
  27. Pantovic, 2013, Coordinated time-dependent modulation of AMPK/Akt/mTOR signaling and autophagy controls osteogenic differentiation of human mesenchymal stem cells, Bone, 52, 524, 10.1016/j.bone.2012.10.024 · DOI · Paper page
  28. Reihill, 2007, AMP-activated protein kinase mediates VEGF-stimulated endothelial NO production, Biochem. Biophys. Res. Commun., 354, 1084, 10.1016/j.bbrc.2007.01.110 · DOI · Paper page
  29. Rosen, 2000, Molecular regulation of adipogenesis, Annu. Rev. Cell Dev. Biol., 16, 145, 10.1146/annurev.cellbio.16.1.145 · DOI · Paper page
  30. Saitoh, 2002, Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site, J. Biol. Chem., 277, 20104, 10.1074/jbc.M201745200 · DOI · Paper page
  31. Salminen, 2011, AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on healthspan and lifespan, J. Mol. Med. Berl., 89, 667, 10.1007/s00109-011-0748-0 · DOI · Paper page
  32. Salt, 2012, Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation, Expert Opin. Investig. Drugs, 21, 1155, 10.1517/13543784.2012.696609 · DOI · Paper page
  33. Schwartz, 2006, Thiazolidinedione use and bone loss in older diabetic adults, J. Clin. Endocrinol. Metab., 91, 3349, 10.1210/jc.2005-2226 · DOI · Paper page
  34. Shea, 2003, BMP treatment of C3H10T1/2 mesenchymal stem cells induces both chondrogenesis and osteogenesis, J. Cell Biochem., 90, 1112, 10.1002/jcb.10734 · DOI · Paper page
  35. Shockley, 2009, PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells, J. Cell Biochem., 106, 232, 10.1002/jcb.21994 · DOI · Paper page
  36. Sun, 2013, Osteoblast-targeted suppression of PPARgamma increases osteogenesis through activation of mTOR signaling, Stem Cells, 31, 2183, 10.1002/stem.1455 · DOI
  37. Tontonoz, 1994, mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer, Genes Dev., 8, 1224, 10.1101/gad.8.10.1224 · DOI · Paper page
  38. Tontonoz, 1994, Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor, Cell, 79, 1147, 10.1016/0092-8674(94)90006-X · DOI · Paper page
  39. Vila-Bedmar, 2010, Adenosine 5'-monophosphate-activated protein kinase-mammalian target of rapamycin cross talk regulates brown adipocyte differentiation, Endocrinology, 151, 980, 10.1210/en.2009-0810 · DOI · Paper page
  40. Yarwood, 1999, Growth hormone-dependent differentiation of 3T3-F442A preadipocytes requires Janus kinase/signal transducer and activator of transcription but not mitogen-activated protein kinase or p70 S6 kinase signaling, J. Biol. Chem., 274, 8662, 10.1074/jbc.274.13.8662 · DOI
  41. Yeh, 1995, Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins, Genes Dev., 9, 168, 10.1101/gad.9.2.168 · DOI · Paper page

Cited by

See all 127

Metadata

Authors
Chen, S. C., Brooks, R., Houskeeper, J., Bremner, S. K., Dunlop, J., Viollet, B., Logan, P. J., Salt, I. P., Ahmed, S. F., & Yarwood, S. J.
Venue
Molecular and Cellular Endocrinology
Publisher
Elsevier BV
Published
2017-01
Volume
440
Pages
57-68
ISSN
0303-7207 (ISSN-L)
OpenAlex
W2553954977
Cited by
127
References
14
FWCI
5.72
Type
journal article
Language
en
Update notices
erratum (2017-03-05)
Open access
hybrid
Licence
Funders
  • Tenovus Scotland (S13/15)
  • Diabetes UK Equipment Grant (11/0004309)
  • British Heart Foundation Project Grant (PG/15/15/31316)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metformin suppresses adipogenesis through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms. https://app.cochat.ai/papers/10.1016/j.mce.2016.11.011
The paper
Chen, S. C., Brooks, R., Houskeeper, J., Bremner, S. K., Dunlop, J., Viollet, B., Logan, P. J., Salt, I. P., Ahmed, S. F., & Yarwood, S. J. (2017). Metformin suppresses adipogenesis through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms. Molecular and Cellular Endocrinology. https://doi.org/10.1016/j.mce.2016.11.011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.